Skip to main
  1. Stocks
  2. Artivion
  3. Forecast
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is viewed favorably because 3Q26 showed resilient execution, with revenue of $123.8 million, about 9% growth year over year, while adjusted EBITDA of $22.5 million also modestly beat expectations. Its core drivers are strengthening as stent grafts rose 12% and On-X increased 13%, and management tightened FY26 guidance to 8%-10% adjusted constant-currency revenue growth while maintaining roughly $95.5 million of adjusted EBITDA. The outlook is further supported by a meaningful product cycle, with AMDS adoption improving after PMA approval and NEXUS positioned to launch on January 1, 2027, alongside supply investments and expanding international reach.

Bears say

Artivion is exposed to meaningful downside from its heavy reliance on international expansion, since non-North American revenue was 49% of total company revenue in 2024 and is vulnerable to tariffs, corruption exposure, compliance burdens, and reimbursement or legal shifts. Its tissue preservation services are also a critical revenue stream, yet supply can be disrupted by regulatory changes, negative publicity, disease-transmission concerns, or restrictions on tissue distribution, creating structural volatility. On top of that, the company faces substantial quality and regulatory risk, including recalls, EU MDR reclassification, possible FDA reclassification of SGPV to Class III, and EtO-related scrutiny, while the bear case already assumes growth slows to the mid-single digits or lower with disappointing new product launches.

Artivion (AORT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Artivion (AORT) Analyst Forecast & Price Prediction

Get the latest Artivion (AORT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Artivion (AORT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Artivion (AORT) Analyst Forecast & Price Prediction

Get the latest Artivion (AORT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Artivion (AORT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AORT stock data and trends